Organization
ImStem Biotechnology
1 clinical trial
1 abstract
Clinical trial
A Phase 1, Dose-Escalating, Open-label Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Single Dose of IV IMS001 in Subjects With Multiple Sclerosis and Treatment Failure to Prior Disease Modifying Treatments (DMTs)Status: Recruiting, Estimated PCD: 2027-12-01
Abstract
Association of patient-reported experience of care with cancer clinical trial participation.Org: National Cancer Institute/National Institutes of Health, ImStem Biotechnology,